When delivered via serum-derived exosomes, miR-15a is internalized by osteosarcoma (OS) cells, where it directly targets GATA-binding protein 2 (GATA2), inhibiting transcription and binding to the MDM2 promoter. Here, GATA2 is linked to osteosarcoma.